AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|
26.1 C
New York
Sunday, July 5, 2026

Tag: change

newssourceFORcompanyinformationcontent1releasesmarket

Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers – FTRE

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortrea Holdings, Inc. ("Fortrea" or the...

“The Most Important Thing About Art is Freedom,” says AR Rahman at IGF London 2025

Oscar-winning composer on scent cinema, AI, and the reinvention of Indian music culture LONDON, June 22, 2025 /PRNewswire/ --  In a deeply personal and expansive...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

Jacob Wang Featured in XYZ Media’s “Next Generation of Innovators” for Developing a Self-Actuated, Eco-Friendly Soft Robot for Drug Delivery

LOS ANGELES, June 22, 2025 (GLOBE NEWSWIRE) -- XYZ Media, a leading media company that bridges educational pursuits with technological innovation, is proud to announce the latest feature in its “Next Generation of Innovators” series, a digital campaign celebrating extraordinary young minds developing innovative solutions to global challenges. The latest series highlights Jacob Wang from Bullis Charter School at Los Altos, CA, for engineering a novel self-actuated soft robot that operates without external power sources or electronics, designed with potential for drug delivery.

Kaanch Network Presale Positions Project Among Top Altcoins and Best Crypto Opportunities of 2025

DUBAI, United Arab Emirates, June 21, 2025 (GLOBE NEWSWIRE) -- Kaanch Network’s token is set to be listed on BitMart and LBank exchanges on June 30th, an important milestone in the project’s mission to revolutionize decentralized finance and asset management. Built on a scalable and affordable Layer 1 blockchain with real-world applications, Kaanch offers developers, business owners, and investors a compelling platform for growth in 2025 and beyond.

No Deposit Casino 2025: Uptown Aces Launches No Deposit Bonus

Uptown Aces has unveiled a new no deposit bonus to incentivize new casino players looking to explore the online gaming world. 
Uptown Aces has unveiled a new no deposit bonus to incentivize new casino players looking to explore the online gaming world.

New Inclave Casinos 2025: Raging Bull Slots Adds Inclave Payment Solution

Raging Bull has introduced Inclave payment solutions to match its broad gaming library, generous bonuses, and secure login. 
Raging Bull has introduced Inclave payment solutions to match its broad gaming library, generous bonuses, and secure login.

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

IIM Udaipur Concludes Executive Education Training Program for PM SHRI School Principals in Collaboration with RSSP Jaipur

UDAIPUR, India, June 21, 2025 /PRNewswire/ -- Indian Institute of Management Udaipur (IIM Udaipur), in collaboration with the Rajasthan School Shiksha Parishad (RSSP), Jaipur,...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsChange

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers